SteelPeak Wealth LLC Sells 9,065 Shares of Bruker Co. (NASDAQ:BRKR)

SteelPeak Wealth LLC trimmed its position in Bruker Co. (NASDAQ:BRKR - Free Report) by 71.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,652 shares of the medical research company's stock after selling 9,065 shares during the period. SteelPeak Wealth LLC's holdings in Bruker were worth $214,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. FMR LLC increased its holdings in shares of Bruker by 21.4% in the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company's stock worth $987,981,000 after buying an additional 2,521,904 shares during the last quarter. Point72 DIFC Ltd increased its stake in Bruker by 4,875.9% in the third quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company's stock valued at $32,470,000 after acquiring an additional 460,722 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Bruker by 1,933.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company's stock valued at $28,331,000 after purchasing an additional 390,057 shares in the last quarter. State Street Corp lifted its stake in Bruker by 9.6% during the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock worth $250,501,000 after purchasing an additional 318,808 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Bruker by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company's stock worth $137,702,000 after purchasing an additional 193,580 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Trading Down 0.6 %

Shares of NASDAQ BRKR traded down $0.32 during trading hours on Tuesday, hitting $56.39. The company's stock had a trading volume of 824,343 shares, compared to its average volume of 1,436,388. The business has a 50-day simple moving average of $58.43 and a 200-day simple moving average of $61.18. The stock has a market cap of $8.55 billion, a price-to-earnings ratio of 27.11, a P/E/G ratio of 3.95 and a beta of 1.16. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66. Bruker Co. has a 12 month low of $48.07 and a 12 month high of $94.86.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business had revenue of $864.40 million for the quarter, compared to analysts' expectations of $866.46 million. During the same period last year, the firm posted $0.74 earnings per share. Bruker's quarterly revenue was up 16.4% on a year-over-year basis. On average, analysts anticipate that Bruker Co. will post 2.4 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date of this dividend was Monday, December 2nd. Bruker's payout ratio is currently 9.62%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. The Goldman Sachs Group raised Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price objective on the stock in a report on Thursday, December 5th. UBS Group initiated coverage on shares of Bruker in a research note on Tuesday, December 10th. They set a "neutral" rating and a $66.00 price target on the stock. Wells Fargo & Company cut their price objective on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th. Bank of America lifted their target price on shares of Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. Finally, Guggenheim restated a "buy" rating on shares of Bruker in a research report on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Bruker currently has a consensus rating of "Moderate Buy" and a consensus price target of $74.45.

Insiders Place Their Bets

In related news, CEO Frank H. Laukien purchased 100,000 shares of Bruker stock in a transaction that occurred on Monday, November 18th. The shares were bought at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares of the company's stock, valued at $1,927,359,688.82. This represents a 0.26 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 28.30% of the company's stock.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.